| 000 | 01701 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515073346.0 | ||
| 264 | 0 | _c20071102 | |
| 008 | 200711s 0 0 eng d | ||
| 022 | _a0268-3369 | ||
| 024 | 7 |
_a10.1038/sj.bmt.1705760 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJabbour, E | |
| 245 | 0 | 0 |
_aTreatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. _h[electronic resource] |
| 260 |
_bBone marrow transplantation _cSep 2007 |
||
| 300 |
_a431-5 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntilymphocyte Serum _xadministration & dosage |
| 650 | 0 | 4 | _aFeasibility Studies |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGraft Rejection |
| 650 | 0 | 4 | _aGraft Survival |
| 650 | 0 | 4 |
_aGraft vs Host Disease _xdrug therapy |
| 650 | 0 | 4 | _aHematopoiesis |
| 650 | 0 | 4 |
_aHematopoietic Stem Cell Transplantation _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPilot Projects |
| 650 | 0 | 4 |
_aSalvage Therapy _xmethods |
| 650 | 0 | 4 |
_aTacrolimus _xtherapeutic use |
| 650 | 0 | 4 |
_aTransplantation Conditioning _xmethods |
| 650 | 0 | 4 | _aTransplantation, Autologous |
| 650 | 0 | 4 |
_aVidarabine _xadministration & dosage |
| 700 | 1 | _aRondon, G | |
| 700 | 1 | _aAnderlini, P | |
| 700 | 1 | _aGiralt, S A | |
| 700 | 1 | _aCouriel, D R | |
| 700 | 1 | _aChamplin, R E | |
| 700 | 1 | _aKhouri, I F | |
| 773 | 0 |
_tBone marrow transplantation _gvol. 40 _gno. 5 _gp. 431-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.bmt.1705760 _zAvailable from publisher's website |
| 999 |
_c17139875 _d17139875 |
||